# Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

> **NCT05547321** · PHASE1 · RECRUITING · sponsor: **Oncomatryx Biopharma S.L.** · enrollment: 150 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** OMTX705
- **DRUG:** Pembrolizumab
- **DRUG:** OMTX705
- **DRUG:** OMTX705
- **DRUG:** OMTX705
- **DRUG:** Tislelizumab (BGB-A317)
- **DRUG:** OMTX705

## Key facts

- **NCT ID:** NCT05547321
- **Lead sponsor:** Oncomatryx Biopharma S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-20
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-11-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05547321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05547321, "Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05547321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*